Abstract
Angiogenesis-driven pathologies, including cancer, are sustained by a preponderance of angiogenic factors over endogenous inhibitors of new-vessel formation. Restoring this balance represents a logical therapeutic strategy to treat these pathologies. Therefore, endogenous inhibitors of angiogenesis, and in particular thrombospondin-1 (TSP-1), are a powerful source of potential antiangiogenic tools. Different therapeutic approaches have been proposed to exploit the antiangiogenic properties of TSP-1, including TSP-1 fragments, synthetic peptides and peptidomimetics, gene therapy strategies and agents that up-regulate TSP-1 expression. This review focuses on the possibility of exploiting TSP-1 for the design of antiangiogenic agents, with particular reference on their use in antineoplastic therapies.
Related Journals
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Diabetes Reviews
Current Neurovascular Research
Current Respiratory Medicine Reviews
Current Pediatric Reviews
Infectious Disorders - Drug Targets
Current Stem Cell Research & Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets
Current Alzheimer Research
Current Aging Science
Related Books
Andrology: Current and Future Developments
Male Infertility: An Integrative Manual of Western and Chinese Medicine
Awake Thoracic Surgery
The Anatomical Foundations of Regional Anesthesia and Acute Pain Medicine Macroanatomy Microanatomy Sonoanatomy Functional anatomy
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents